What is the price difference between the original drug and generic drug of erdafitinib?

Erdafitinib (Erdafitinib) is a targeted therapy drug targeting fibroblast growth factor receptor (FGFR) mutations. It is mainly used to treat locally advanced or metastatic urothelial carcinoma (bladder cancer) , especially for patients carrying FGFR2 or FGFR3 gene mutations. Its launch provides an important molecular targeted alternative to traditional treatment methods, and has certain clinical value especially for patients who have failed previous chemotherapy or are intolerant to immunotherapy. By targeting the abnormal activation of the FGFR signaling pathway, erdafitinib can effectively block the proliferation and metastasis pathways of tumor cells, achieving the therapeutic purpose of delaying disease progression. Because of its highly specific target, it plays an important role in the trend of precision medicine and personalized medicine.

In China, erdafitinib has been approved for marketing under the trade name BALVERSA (BALVERSA), but it has not yet been included in the medical insurance catalog, resulting in a heavy financial burden. Currently, common domestic specifications include 3mg, 4mg and 5mg tablets in different packaging to meet the needs of dose adjustment. Due to insufficient medical insurance coverage and restrictions on distribution channels, it is difficult for patients to obtain the drug in domestic hospitals.

In contrast, overseas channels have become another important way for patients to purchase drugs. Currently, most of the original drugs on the market are Hong Kong versions, which need to be obtained through regular Hong Kong pharmacies. The price is generally as high as more than 20,000 yuan per box, and the overall cost is not low. In addition, some patients choose to use overseas generic versions to relieve financial pressure. Currently, generic drugs mainly come from pharmaceutical factories in Laos or Bangladesh, such as Yaopin International, and their prices usually range from a few hundred to two thousand yuan, which is significantly lower than the original drugs.

For patients considering using generic drugs, it is the first prerequisite to understand whether their sources are reliable and whether their safety is guaranteed. It is worth noting that erdafitinib, as a molecularly targeted drug, must be confirmed by genetic testing before use. Otherwise, the efficacy of erdafitinib is difficult to predict. Therefore, whether to choose original drugs or generic drugs should be considered comprehensively under the guidance of professional doctors and cannot be based solely on price.

References：https://www.balversa.com/